Skip to content

    Colorectal Cancer Health Center

    Font Size

    Colorectal Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Evidence of Benefit

    Table 3. Randomized Controlled Screening Trials: Fecal Occult Blood Testing

    Site Population Size Positivity Rate (%) % Cancers Localizeda Testing Interval Relative Mortality Reduction
    a % Localized = T1-3 N0 M0.
    Screened Control
    Minnesota[5,28] 48,000 Unrehydrated: 2.4% 59 53 Annual 33%
    Rehydrated: 9.8% Biennial 21%
    United Kingdom[10] 150,000 Unrehydrated: 2.1% 52 44 Biennial 15%
    Denmark[14] 62,000 Unrehydrated: 1.0% 56 48 Biennial 18%
    Sweden[29] 68,308 Unrehydrated: 1.9% 52 50 16%
    Rehydrated: 5.8%

    Newer FOBTs: Nonrandomized Controlled Trial Evidence

    The immunochemical FOBT (iFOBT) was developed to detect intact human hemoglobin. The advantage of iFOBT over gFOBT is that it does not detect hemoglobin from nonhuman dietary sources. It also does not detect partly digested human hemoglobin that comes from the upper respiratory or GI tract. Preliminary studies of several commercially developed iFOBT tests define their sensitivity and specificity compared with concurrently performed colonoscopy. These studies also examine these outcomes for different cut points, and the benefit of multiple versus single stool samples.[30] Generally, iFOBT testing is more sensitive for cancers than for benign neoplasias. As expected, higher cut points decrease sensitivity and increase specificity.

    In one study, 2,188 patients scheduled for colonoscopy because of an elevated risk due to personal or family history of colorectal neoplasm, positive gFOBT result, change in bowel habits, anemia, abdominal pain with weight loss, or anal symptoms were invited to participate in a comparative assessment of iFOBT against colonoscopy findings. After exclusions for health and cognitive reasons, 1,859 patients were offered iFOBT, 1,116 patients adhered to the protocol, and 1,000 patients completed the procedure. Sensitivity and specificity were calculated at various cut-points. At a cut-point of 100 ng/mL, sensitivity and specificity were, respectively, 88.2% and 89.7% for cancer and 61.5% and 91.4% for any clinically significant neoplasia (cancer and advanced polyps). At 150 ng/mL the respective sensitivities and specificities were 82.4% and 91.9% for cancer and 53.8% and 95% for any clinically significant neoplasia. Calculations were based on the most severe pathologic finding from colonoscopy and the highest fecal-hemoglobin concentration measured by iFOBT applied to three stool samples collected prior to the colonoscopy. Stool samples were collected by patients following iFOBT kit instructions and analyzed by the OC-MICRO analyzer (from the Eiken Chemical Company in Tokyo, Japan).[31]

    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    The right diagnosis is the most important factor.
    man with a doctor
    Our health check will steer you in the right direction.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    bladder cancer x-ray
    Do you know the warning signs?
    Colon vs Rectal Cancer
    New Colorectal Treatments
    can lack of sleep affect your immune system
    Cancer Facts Quiz
    Virtual Colonoscopy
    Picture of the Colon
    Vitamin D